Clinicopathologic and Molecular Characterization of Adult <i>1p/19q</i> Non-codeleted Oligodendrogliomas

Linyun LI; Zongfang LI; Guomiao SU; Shiyue LIU; Yanxi LI

doi:10.12259/j.issn.2095-610X.S20240802

Volume 45 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(8): 7-16

Linyun LI, Zongfang LI, Guomiao SU, Shiyue LIU, Yanxi LI. Clinicopathologic and Molecular Characterization of Adult 1p/19q Non-codeleted Oligodendrogliomas[J]. Journal of Kunming Medical University, 2024, 45(8): 7-16. doi: 10.12259/j.issn.2095-610X.S20240802

Citation:

Linyun LI, Zongfang LI, Guomiao SU, Shiyue LIU, Yanxi LI. Clinicopathologic and Molecular Characterization of Adult 1p/19q Non-codeleted Oligodendrogliomas[J]. Journal of Kunming Medical University, 2024, 45(8): 7-16. doi: 10.12259/j.issn.2095-610X.S20240802

Citation:

PDF( 2094 KB)

Clinicopathologic and Molecular Characterization of Adult 1p/19q Non-codeleted Oligodendrogliomas

doi: 10.12259/j.issn.2095-610X.S20240802

1.
Dept. of Radiology
2.
Dept. of Pathology ，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2024-04-07
Available Online: 2024-07-06
Publish Date: 2024-08-05

Abstract

Abstract

Objective To investigate the clinicopathologic and other molecular markers features of oligodendrogliomas in adults with non-codeletion of 1p/19q. Methods 326 cases of oligodendrogliomas, anaplastic oligodendrogliomas, oligoastrocytomas, and anaplastic oligoastrocytomas diagnosed by histopathology after surgical resection were collected. The polymorphism of chromosome 1p and 19q were analyzed by fluorescence in situ hybridization （FISH）. Isocitrate dehydrogenase （IDH） 1/2 mutation, TP53 and promoter of telomerase reverse transcriptase （TERTp） were detected by Sanger sequencing. The expression levels of ATRX, PDGFRA, EGFR, CIC, FUBP1, INA, and PTEN were detected by immunohistochemical staining, and methylation specific PCR （MSP） was used to detect the methylation of MGMT promotor. Results The 1p/19q status of 326 adult oligodendrogliomas showed that 37.6% of the tumors were 1p/19q non-codeletion, and more than half of the 1p/19q non-codeleted oligodendrogliomas showed lack of expression of p53 and ATRX, the defining astrocytic markers. In the cohort of 1p/19q non-codeleted "oligodendrogliomas", patients with younger age （<45 years）, WHO grade 2, and typical oligodendroglioma histomorphology had a better prognosis（P < 0.01）, and the typical histomorphology of oligodendrogliomas was associated with TERTp mutation status, p53 expression, EFGR expression, PDGFRA expression（P < 0.05）. The expression of FUBP1, TERT, MGMT, PDGFRA, EGFR, PTEN, INA, and CIC was not found to have significant prognostic value（P > 0.05）. Conclusion According to the 5th edition of the 2021 WHO Classification of Tumors of the Central Nervous System, astrocytomas do not account for all 1p/19q non-codeleted oligodendrogliomas, and 1p/19q non-codeleted oligodendrogliomas may represent a distinct subgroup of diffuse gliomas.
- Oligodendrogliomas,
- 1p/19q non-codeletion,
- Molecular maker

FullText(HTML)

References(29)

References

[1]	Louis D N,Perry A,Wesseling P,et al. The 2021 WHO classification of tumors of the central nervous system: A summary[J]. Neuro Oncol,2021,23(8):1231-1251. doi: 10.1093/neuonc/noab106
[2]	王樑,潘亚文,屈延,等. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)成人型弥漫性胶质瘤分类解读[J]. 中国现代神经疾病杂志,2021,21(9):783-790. doi: 10.3969/j.issn.1672-6731.2021.09.008
[3]	Li Y X, Shi Z, Aibaidula A, et al. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic [J]. Oncotarget, 2016, 7（40）: 64615-64630. Li Y X,Shi Z,Aibaidula A,et al. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic [J]. Oncotarget,2016,7(40): 64615-64630.
[4]	Bettegowda C,Agrawa N,Jiao Y,et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma[J]. Science,2011,333(6048):1453-1455. doi: 10.1126/science.1210557
[5]	Ducray F,Mokhtari K,Criniere E,et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas[J]. Eur J Cancer,2011,47(5):802-808. doi: 10.1016/j.ejca.2010.11.031
[6]	Eigenbrod S,Roeber S,Thon N,et al. α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status[J]. J Neuropathol Exp Neurol,2011,70(11):970-978. doi: 10.1097/NEN.0b013e3182333ef5
[7]	Brito C,Azebedo A,Esreves S,et al. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification,TERT mutations,PTEN deletion and MGMT methylation[J]. BMC Cancer,2019,19(1):968. doi: 10.1186/s12885-019-6177-0
[8]	Martinho O,Longatto-filho A,Lambros M B,et al. Expression,mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas[J]. Br J Cancer,2009,101(6):973-982. doi: 10.1038/sj.bjc.6605225
[9]	Louis D N,Ohgaki H,Wiestler O D,et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol,2007,114(2):97-109. doi: 10.1007/s00401-007-0243-4
[10]	Reuss D E,Sahm F,Schrimpf D,et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an“integrated”diagnostic approach for adult astrocytoma,oligodendroglioma and glioblastoma[J]. Acta Neuropathol,2015,129(1):133-146. doi: 10.1007/s00401-014-1370-3
[11]	Takami H,Yoshida A,Fukushima S,et al. Revisiting TP53 mutations and Immunohistochemistry—a comparative study in 157 diffuse gliomas[J]. Brain Pathol,2015,25(3):256-265. doi: 10.1111/bpa.12173
[12]	Canale M,Petracci E,Delmonte A,et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with firstline tyrosine kinase inhibitors[J]. Clin Cancer Res,2017,23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966
[13]	Chan A K,Pang J C,Chung N Y,et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors[J]. Mod Pathol,2014,27(3):332-342. doi: 10.1038/modpathol.2013.165
[14]	Gusyatiner O,Hegi M E. Glioma epigenetics: From subclassification to novel treatment options[J]. Semin Cancer Biol,2018,51:50-58. doi: 10.1016/j.semcancer.2017.11.010
[15]	苏玉金,杜江,王军梅,等. 568 例少突胶质细胞肿瘤中染色体 1p/19q 缺失和多体特点分析[J]. 中国医刊,2017,52(3):57-60. doi: 10.3969/j.issn.1008-1070.2017.03.018
[16]	Cairncross G,Wang M,Shaw E,et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402[J]. J Clin Oncol,2013,31(3):337-343. doi: 10.1200/JCO.2012.43.2674
[17]	Giannini C,Burger P C,Berkey B A,et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology,1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402[J]. Brain Pathol,2008,18(3):360-369. doi: 10.1111/j.1750-3639.2008.00129.x
[18]	Ohba S,Kuwahara K,Yamada S,et al. Correlation between IDH,ATRX,and TERT promoter mutations in glioma[J]. Brain Tumor Pathol,2020,37(2):33-40. doi: 10.1007/s10014-020-00360-4
[19]	张成娟,魏冰,郭永军,等. 胶质瘤中TERT启动子突变的研究进展[J]. 河南医学研究,2017,26(6):1018-1019. doi: 10.3969/j.issn.1004-437X.2017.06.026
[20]	Liu H,Xu C,Diplas B H,et al. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells[J]. Neuro Oncol,2023,25(9):1563-1575.
[21]	Nandakumar P,Mansouri A,Das S. The role of ATRX in glioma biology[J]. Front Oncol,2017,7:236. doi: 10.3389/fonc.2017.00236
[22]	Killela P J,Reitman Z J,Jiao Y,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal[J]. Proc Natl Acad Sci U S A,2013,110(15):6021-6026. doi: 10.1073/pnas.1303607110
[23]	Bedics G,Szőke P,Bátai B,et al. Novel,clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas[J]. Sci Rep,2023,13(1):18436.
[24]	Eckel-Passow J E,Lachance D H,Molinaro A M,et al. Glioma groups based on 1p/19q,IDH,and TERT promoter mutations in tumors[J]. Sci RepN Engl J Med,2015,372(26):2499-2508. doi: 10.1056/NEJMoa1407279
[25]	樊小龙,杨子辰. 成人型弥漫性胶质瘤的分子分型研究进展[J]. 北京师范大学学报(自然科学版),2023,59(1):38-42. doi: 10.12202/j.0476-0301.2022153
[26]	Sun Y,Zhang W,Chen D,et al. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA[J]. Proc Natl Acad Sci U S A,2014,111(9):3538-3543. doi: 10.1073/pnas.1313814111
[27]	孙晓玲,张晓娟,张清泉,等. TP53、EGFR、PDGF在星形胶质细胞瘤进展中的表达及意义[J]. 广东医学,2019,40(12):1750-1753.
[28]	Chen C C L,Deshmukh S,Jessa S,et al. Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis [J]. Cell,2020,183(6): 1617-1633 e22.
[29]	Horbinski C,Hobbs J,Cieply K,et al. EGFR expression stratifies oligodendroglioma behavior [J]. Am J Pathol,2011,179(4): 1638-1644.

Relative Articles(20)

Relative Articles

[1]	Xuedan WANG, Yifan LIU, Zihan YANG, Dandan ZHANG, Yi DUAN, Zhihui YANG. Analysis of the Clinicopathological and Molecular Features of Appendiceal Mucinous Neoplasms. Journal of Kunming Medical University, 2024, 45(7): 42-48. doi: 10.12259/j.issn.2095-610X.S20240706
[2]	Bowen TAN, Yun LIANG, Huan CHEN, Yi LEI, Yuhan WANG, Yan TIAN. The Prognostic Value of Preoperative Peripheral Blood Inflammatory Markers Combined with Tumor Markers in Resectable Colon Cancer Patients. Journal of Kunming Medical University, 2024, 45(12): 1-5.
[3]	Yi FENG, Xiaofeng WANG, Ximin BAI, Sheng YAO, Juntao DANG, Yunjie ZHAO, Bing CAI. miR-149-5p Regulates Malignant Biological Behavior of Glioma Cells Through MSH5/WNT Signaling Pathway. Journal of Kunming Medical University, 2023, 44(8): 59-70. doi: 10.12259/j.issn.2095-610X.S20230823
[4]	Dong WANG, Bibo GAO, Huiying SUN, Denghui LENG, Xiaoping RAN, Wen LIN. miR-216b-5p Promotes Ferroptosis in Glioblastoma Cells by Targeting NCOA3. Journal of Kunming Medical University, 2023, 44(8): 44-52. doi: 10.12259/j.issn.2095-610X.S20230805
[5]	Jinxi YUE, Linjun WAN, Ruiling ZHANG, Xiaoran ZHANG, Ouya LIU, Xiaofan YU, Qingqing HUANG, Zongfang REN. Clinical Significance of a Marker of Thrombin Activity-fibrin Monomer after Surgery. Journal of Kunming Medical University, 2023, 44(3): 87-91. doi: 10.12259/j.issn.2095-610X.S20230325
[6]	Liang ZHANG, Baoquan WANG, Xifeng LEI, Xu WANG, Yang KE, Wei ZHANG. Effect of miR-29c-3p/IGF1 Molecular Axis on Activation，Proliferation and Apoptosis of Hepatic Stellate Cells. Journal of Kunming Medical University, 2023, 44(9): 7-14. doi: 10.12259/j.issn.2095-610X.S20230926
[7]	Hualei DAI, Chengcheng HU, Guimin ZHANG, Siming TAO, Jiankun CHEN. Screening Biomarkers of Astragalus Membranaceus for Hypertensive Ventricular Remodeling Based on Network Pharmacology and Molecular Docking. Journal of Kunming Medical University, 2023, 44(8): 27-36. doi: 10.12259/j.issn.2095-610X.S20230819
[8]	Yan WANG, Rong DING, Lvling ZHANG, Ruohua WANG, Xiaoling ZHAO, Na MA. Efficacy of Blood Transfusion Combined with Chemoradiotherapy in Patients with Colorectal Cancer and its Effect on Tumor Markers and T Lymphocyte Levels. Journal of Kunming Medical University, 2022, 43(8): 61-65. doi: 10.12259/j.issn.2095-610X.S20220809
[9]	Yu Chao Jun , Zhao Qian Hao , Zhao Ning Hui . . Journal of Kunming Medical University, 2020, 41(07): 11-16.
[10]	Liu Chong , Cao Hui , Yang Cai Cai , Wang Zhen . . Journal of Kunming Medical University, 2020, 41(06): 32-38.
[11]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University, 2020, 41(09): 32-37.
[12]	Luo Shao Lei , Ma Li Ju , Ma Teng Fei , Shao Wen Ping . Diagnostic Value of Combined Detection of Multiple Tumor Markers in Colorectal Cancer. Journal of Kunming Medical University, 2017, 38(10): 101-106.
[13]	Jiang Hong Ying , Dou Li Na , Liao Yun Juan , Zeng Yi , Bai Yi Hua , Yang Min . Clinical Value of Myocardial Injury Markers in Evaluating Cardiac Structure and Function of Chronic Kidney Disease Patients without Dialysis. Journal of Kunming Medical University, 2017, 38(10): 50-54.
[14]	Liu Yu . The Value of Renal Tubular Injury Biomarkers in Diagnosis of Primary Nephrotic Syndrome. Journal of Kunming Medical University,
[15]	Yang Shao Hua . . Journal of Kunming Medical University,
[16]	Li Jing Hui . . Journal of Kunming Medical University,
[17]	Wang Hui Ming . . Journal of Kunming Medical University,
[18]	Rui Qiao An . . Journal of Kunming Medical University,
[19]	. Antitumor Activity of the Extracts from Panax Notoginseng in Vitro and Components Analysis. Journal of Kunming Medical University,
[20]	Ma Yong Hong . . Journal of Kunming Medical University,